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ABSTRACT
Degenerate splice site sequences mark the intron
boundaries of pre-mRNA transcripts in multicellular
eukaryotes. The essential pre-mRNA splicing factor
U2AF65 is faced with the paradoxical tasks of accur-
ately targeting polypyrimidine (Py) tracts preceding
30 splice sites while adapting to both cytidine and
uridine nucleotides with nearly equivalent
frequencies. To understand how U2AF65 recognizes
degenerate Py tracts, we determined six crystal
structures of human U2AF65 bound to cytidine-
containing Py tracts. As deoxy-ribose backbones
were required for co-crystallization with these Py
tracts, we also determined two baseline structures
of U2AF65 bound to the deoxy-uridine counterparts
and compared the original, RNA-bound structure.
Local structural changes suggest that the
N-terminal RNA recognition motif 1 (RRM1) is more
promiscuous for cytosine-containing Py tracts than
the C-terminal RRM2. These structural differences
between the RRMs were reinforced by the
specificities of wild-type and site-directed mutant
U2AF65 for region-dependent cytosine- and
uracil-containing RNA sites. Small-angle X-ray scat-
tering analyses further demonstrated that Py tract
variations select distinct inter-RRM spacings from
a pre-existing ensemble of U2AF65 conformations.
Our results highlight both local and global conform-
ational selection as a means for universal 30 splice
site recognition by U2AF65.
INTRODUCTION
Pre-mRNA splicing removes non-coding introns and
regulates most human transcripts (1); however, the mech-
anisms by which the splice sites are identiﬁed and
regulated are not well understood. Splicing ﬁdelity is
assisted by an ATP-dependent series of checkpoints
during the assembly of >100 proteins and ﬁve small
nuclear (sn)RNAs into the active spliceosome [reviewed
in (2)]. Consensus sequences mark the 50 and 30 splice
sites at the intron-exon boundaries of the pre-mRNA.
Nevertheless, to be distinguished and regulated in a
speciﬁc manner, the ‘weak’ regulated splice sites of multi-
cellular organisms often deviate from the optimum con-
sensus of ‘strong’ constitutive splice sites (3). The
spliceosome is directed to the 30 splice site of the
pre-mRNA by a polypyrimidine (Py) tract located
between the branchpoint sequence and an AG dinucleo-
tide (Figure 1A). The Py tract exempliﬁes the variability of
human splice site signals. Cytidines precede the 30 splice
site at frequencies approaching those of uridine (35 and
45%, respectively) (4,5), yet cytidine and uridine confer
different Py tract activities. Increasing the number of
uridines in a Py tract generally increases use of an
adjacent 30 splice site (6–8). Isolated cytidine nucleotides
in a uridine-rich Py tract can support or even enhance the
use of an adjacent 30 splice site (6,9), yet several consecu-
tive cytidines can abolish detectable splicing (7,9).
Mutations that compromise recognition of splice site
signals can be lethal or lead to genetic diseases and
cancer [reviewed in (10,11)], such as shortening of a cftr
Py tract that is responsible for some cases of cystic ﬁbrosis
(12,13). Consequently, the spliceosomal proteins and
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Figure 1. Crystal structures of U2AF65 bound to diverse Py tracts. (A) Splicing factors recognizing the 30 splice site. A pictogram of the primate Py
tract consensus derived from (4) is inset below. The C- to N-terminal orientation of the U2AF65 domains recognize the 50–30- direction of the
pre-mRNA. BPS, branchpoint sequence; Py tract, polypyrimidine tract; AG dinucleotide. The U2AF65 RRMs are numbered in sequence and ‘U’
indicates the C-terminal UHM. The U2AF65 domains and inter-RRM linker sequences are given in Supplementary Figure S1. (B) The nomenclature,
Py tract sequences, resolution limits and crystallographic Rfactors are listed for the dU2AF
651,2 crystal structures. The binding registers of the Py
tracts are aligned relative to the seven nucleotide binding sites of the original dU2AF651,2/rU12 structure (PDB ID 2G4B). Electron density maps
such as those shown in Supplementary Figure S2 were used to assign the Br-dU positions. Py tracts of distinct copies in the crystallographic
asymmetric unit are listed separately (oligonucleotides ‘P’ and ‘E’; (Br-dU5)dC1 also includes oligonucleotides ‘H’ and ‘K’). Alternative binding
registers marked ‘a’ and ‘b’ are italicized. Nucleotides marked with grey font lack interpretable electron density and were not included in the ﬁnal
structures. Supplementary Table S1 details the crystallographic data and reﬁnement statistics.
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snRNAs must overcome the challenge of recognizing de-
generate signal sequences embedded within pre-mRNAs
that are thousands of nucleotides long.
The U2 small nuclear ribonucleoprotein auxiliary factor
65 kDa (U2AF65) universally recognizes degenerate Py
tracts preceding 30 splice sites during the early stages of
pre-mRNA splicing (14–17) (Figure 1A), and there facili-
tates ATP-dependent association of the U2 snRNP (14).
U2AF65 is essential for vertebrate development (18), and
speciﬁc U2AF65 deﬁciencies are associated with cystic
ﬁbrosis (19), myotonic dystrophy (20) and several
cancers (21–23). U2AF65 recognizes the Py tract via two
central RNA recognition motifs (RRM1 and RRM2)
(17,24) (Figure 1A, Supplementary Figure S1A). Our
structure of the core RRM1 and RRM2-containing
domain of U2AF65 bound to an optimal poly-uridine
(poly-rU) RNA (25) reveals that U2AF65 forms speciﬁc
hydrogen bonds with the edges of the uracil bases,
including the N3 and O4 atoms where cytosine differs
from uracil. Subsequent NMR characterizations con-
ﬁrmed the interactions of the individual U2AF65 RRMs
with uridines in solution (26), although the inter-RRM
arrangements differ from the solution conﬁguration
owing to an internal deletion of the inter-RRM linker
that was required for crystallization (27). The observation
of apparently speciﬁc hydrogen bonds between U2AF65
and the uracil bases served to highlight the question:
how can U2AF65 universally target the diverse Py tracts
of multicellular eukaryotes?
To address this question, here we report six crystal
structures of human U2AF65 bound to cytosine-
containing Py tracts. We also determined and compare
the original RNA-bound structure with two crystal struc-
tures of the deoxy-uridine (dU) containing counterparts,
as deoxy-ribose backbones were required for co-
crystallization of these Py tracts. Structural differences,
coupled with the region-dependent Py tract afﬁnities of
U2AF65 and site-directed mutants and small-angle X-ray
scattering (SAXS) data of U2AF65 complexes with various
Py tracts, suggest that U2AF65 adapts to degenerate splice
site signals through conformational selection of a promis-
cuous N-terminal RRM1 and a stringent C-terminal
RRM2.
MATERIALS AND METHODS
Crystallographic analyses
Given that 7 of 12 co-crystallized uridines were observed
in the original structure (27), we obtained new crystal
forms of a U2AF65 variant (dU2AF651,2, including
residues 148–237 and 258–336) bound to minimal,
seven-nucleotide sites and marked by 5-bromo-uridines
(Br-dU) to deﬁne the oligonucleotide-binding registers
(Figure 1B, Supplementary Table S1, Supplementary
Figure S2). A deoxy-ribose backbone for the uracil bases
was required to co-crystallize the 7-mer oligonucleotides;
the U2AF65 protein binds deoxy-ribonucleotides with rea-
sonable afﬁnity (25,28) and contacts only a single 20
hydroxyl group at the 50 terminus of the poly-rU RNA
(25). We previously demonstrated that the U2AF65
variant (dU2AF651,2, including residues 148–237 and
258–336) used for crystallization exhibits similar RNA
afﬁnities, splicing efﬁciencies and protein/RNA contacts
as the unmodiﬁed U2AF65 counterpart (25,27,29). The
interdomain linker is poorly conserved (Supplementary
Figure S1B), and residues 238–257 can be replaced with
unrelated sequences without penalizing the afﬁnity or
ability of U2AF65 to support pre-mRNA splicing (29).
Human U2AF65 constructs were expressed and puriﬁed
as described (27). Structures were determined by molecu-
lar replacement using the RRMs of PDB ID 2G4B as
search models and reﬁned using REFMAC5 (30).
Puriﬁed DNA oligonucleotides were purchased from
Integrated DNA Technologies, Inc. Protein and DNA
concentrations were estimated using the respective absorb-
ance at 280 nm or 260 nm and calculated molar extinction
coefﬁcients (31,32). Protein (20mg/mL) and DNA were
mixed in 1:1.2 molar ratio with 4mM [N,N’-Bis(3-D-
gluconamidopropyl) deoxycholamide]. Crystals were
grown by the hanging drop method against a reservoir
solution of 1.5–1.6M ammonium sulfate, 10% dioxane
and 0.1M 2-(N-morpholino)ethanesulfonic acid (pH 6.0)
at 4C and ﬂash cooled following stepwise transfer to 21%
glycerol as the cryoprotectant. Data collection and reﬁne-
ment statistics are reported in Supplementary Table S1.
Surface plasmon resonance experiments
Surface plasmon resonance (SPR) experiments were
completed as described previously (25) with minor modiﬁ-
cations. To reduce steric effects, a 14-atom linker separated
the 50 biotin used for immobilization from the 50 phosphate
of the oligonucleotide. As the on/off rates approach the
limit for reliable measurement, the average equilibrium
response at each concentration was ﬁt to a steady-state
binding model. Repeated washes with the running buffer
were sufﬁcient to regenerate the surface following each
injection. At least two independent experiments were
repeated for each oligonucleotide/protein combination,
and the average KDs are reported in Table 1.
Representative sensorgrams and binding curves are
shown in Supplementary Figure S6. Isothermal titration
calorimetry (ITC) experiments described in
Supplementary Figure S7 independently conﬁrmed the
preference ofU2AF651,2 to bind 50-4rU over 30-4rURNAs.
SAXS analyses
Following size exclusion chromatography to prepare
monodisperse samples, the appropriate protein:RNA
stoichiometries were veriﬁed by the absorbance ratios of
the ﬁnal SAXS samples at 280 nm and 260 nm. SAXS
samples were free of interparticle effects based on the
agreement of scattering and Guinier plots over a range
of concentrations (Supplementary Figure S8). Ensembles
of 20 different PDB structure ﬁles were ﬁt using the
program EOM (33) and signiﬁcantly improved the 2
values over single models (Supplementary Table S2). As
the 13-nucleotide Py tracts contribute only 11% of the
total scattering mass, the SAXS data primarily reﬂect
the protein conformations. The rigid body models are
composed of the RRM1 and RRM2 structures from
Nucleic Acids Research, 2013, Vol. 41, No. 6 3861
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PDB ID 2G4B and U2AF Homology Motif (UHM)
structure from PDB ID 1OPI connected by ab initio
linkers.
RESULTS
Structures of human U2AF65 bound to
cytidine-containing sites
To understand how U2AF65 adapts to cytidines, we
determined eight structures of dU2AF651,2 bound to
oligonucleotides, six of which contained single cytidines
(Figure 1B, Supplementary Table S1). We previously
determined the structure of a U2AF65 variant
(dU2AF651,2 lacking residues 238–257 of the inter-RRM
linker) bound to a 12-mer poly-rU RNA (rU12) (25). The
dU2AF651,2 protein is required for crystallization (27)
and exhibits similar RNA afﬁnities, splicing efﬁciencies
and protein/RNA contacts as the wild-type U2AF651,2
counterpart (25–27,29). To distinguish cytidine from
uridine, we co-crystallized dU2AF651,2 with the core
deoxy-uridine (dU) 7-mer with the sequence register
marked by 5-Br-dU (Supplementary Figure S2). A DNA
backbone for the uracil bases was required for
co-crystallization of these shorter oligonucleotides with
U2AF65. The U2AF65 protein binds a 20-mer dU oligo-
nucleotide with a 4–7-fold apparent decrease in afﬁnity
relative to the RNA counterpart, consistent with a
single 20 hydroxyl contact with the 50 terminal nucleotide
in the crystal structure of dU2AF651,2 bound to poly-rU
RNA (25).
The structures of two baseline Br-dU-containing
complexes (Br-dU3 and Br-dU5) were determined at 2.5
and 2.2 A˚ resolution, respectively, for comparison with
the cytidine-containing counterparts. Based on the omit
electron density maps, the Br-dU3 strands exhibited alter-
native conformations, i.e. a mixed population of the two
binding registers with the Br-dU in both the fourth and ﬁfth
rather than the third binding sites (Figure 1B,
Supplementary Figure S2A). The slipped binding register
enables the halogen substituent to participate in favourable
aromatic stacking interactions with U2AF65 side chains
(34) (Figure S2I) and at the ﬁfth position, is near positively
charged K225 and R227 residues (Figure 4A). The intro-
duction of cytidines altered the apparent preference for
U2AF65 to bind Br-dU at the fourth or ﬁfth sites, in
most cases by stabilizing one of the two pre-existing alter-
native conformations (Figure 1B). The altered binding
registers of the cytidine-containing oligonucleotides,
coupled with local changes at the individual sites described
later in the text, support the hypothesis that certain
U2AF65 sites can accommodate cytidines more readily
than others. Based on these observations, we subsequently
focused on oligonucleotides containing Br-dU at the ﬁfth
position of the sequence (Br-dU5). For all complexes of
dU2AF651,2 with Br-dU5-containing oligonucleotides, the
bromine appeared at the expected ﬁfth nucleotide binding
site (Supplementary Figure S2E).
Each structure offers two crystallographically independ-
ent views of the protein/oligonucleotide complex
(Figure 2A), with the exceptions of four copies for the
dU2AF651,2/(Br-dU5)dC1 structure and one copy for
the original dU2AF651,2/rU12 structure. The backbone
conformations of the individual RRM1 or RRM2
domains were nearly identical among the structures
(rmsd 0.25–0.35 A˚ between Ca atoms of the RRMs),
whereas the relative RRM positions differ (rmsd 6–7 A˚
between Ca atoms of the overall polypeptide chains)
(Supplementary Figure S3A). The overall domain ar-
rangements are likely to be inﬂuenced by the internal
Figure 2. Overall structures of U2AF65 recognizing Py tracts.
(A) Overall packing of the two U2AF65/Py tract complexes in the crys-
tallographic asymmetric units. Protein ‘A’ (blue) respectively binds the
50 and 30 regions of oligonucleotides ‘E’ and ‘P’ (magenta); Protein ‘B’
(green) respectively binds the 50 and 30 regions of oligonucleotides ‘P’
and symmetry-related ‘Esym’ (pink). The boxed complex is expanded in
B. (B) Representative structure of dU2AF651,2 (chain ‘A’) bound to the
Br-dU5 oligonucleotide. The four nucleotides contacting each RRM are
coloured magenta and numbered as discussed in the text. The central,
fourth nucleotide contacts both RRM1 and RRM2 by crystallographic
symmetry as shown in A. Top, view into the face of RRM1 bound to
the 30 region in an identical orientation as the boxed polypeptide in A;
Bottom, view into the face of RRM2 bound to the 50 region following
2-fold rotation about the y-axis.
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deletion within inter-RRM linker that is required for crys-
tallization and hence also differ from the NMR-based
model for the wild-type U2AF651,2 bound to a 9-mer
poly(rU) RNA (26). Nevertheless, the nucleotide inter-
actions by the individual RRMs in the crystal structures
agree with the solution data (26) and as such offer the
means to illustrate the local U2AF65 interactions with
cytidine-substituted Py tracts at high resolution.
The dU4-dU7 of both complexes and dU1-dU4 in one of
the two complexes (oligonucleotide ‘E’) in the crystallo-
graphic asymmetric unit correspond to the dU2AF651,2-
bound rU12-conformation (rmsd of matching O4, N3, O2
atoms is 0.48 A˚ for dU4-E–dU7-E/rU4–rU7, 0.50 A˚ for
dU4-P–dU7-P/rU4–rU7 and 0.73 A˚ rmsd for dU1-E–
dU4-E/rU4–rU7) (Supplementary Figure S3B and D). The
dU1 and dU2 positions of the other crystallographically in-
dependent complex (oligonucleotide ‘P’ in Figure 2) differ
from oligonucleotide ‘E’ and the RNA counterpart
(rmsd is 6.4 A˚ for dU1-P – dU4-P/rU1 – rU4 compared
with 0.42 A˚ for dU3-P – dU4-P/rU3 – rU4)
(Supplementary Figure S3C). The altered positions of the
dU1-P and consequently dU2-P nucleotides likely arise
from weakened interactions in the absence of the rU1 50
terminal phosphate and hydroxyl group (Supplementary
Figure S4). Apart from these differences in the ﬁrst and
second nucleotides of oligonucleotide ‘P’, U2AF65 recog-
nizes the dUs in a similar manner as the uridines of the
rU12 RNA (Figures 3–4, Supplementary Figure S5).
Figure 3. Structural comparison of U2AF65 RRM2 recognizing uracil versus cytosine. (A) First nucleotide binding sites. The dU1 and dU2 of
Br-dU5 oligonucleotides ‘E’ correspond to the binding sites of the RNA counterpart and are shown in A and B. The distinct binding sites of dU1
and dU2 from the Br-dU5 ‘P’ oligonucleotides are shown in Supplementary Figure S4A and B. SigmaA-weighted 2jFoj-jFcj electron density maps are
contoured at 1 s. The dC1 is disordered and lacks apparent electron density in all four oligonucleotides (‘E’, ‘H’, ‘K’ and ‘P’) of the (Br-dU5)dC1
structure. The neighbouring dU2 of (Br-dU5)dC1 oligonucleotide ‘P’ also is disordered. (B) Second nucleotide binding sites. One example of cytidine
in the second binding site of oligonucleotide ‘E’ is available from the (Br-dU5)dC2 structure. The two alternative conformations of dC2-E are shown
in separate panels for clarity. The distinct cytidine binding site of (Br-dU5)dC2 oligonucleotide ‘P’ is shown in Supplementary Figure S4C and is
nearly identical for (Br-dU3)dC2-P. (C) Third nucleotide binding sites. The U2AF65 interactions are nearly identical with the dU3 nucleotide of the
Br-dU5 structure and corresponding dU2 nucleotide of Br-dU3 structure in both oligonucleotides ‘E’ and ‘P’. One example of cytidine in the third
binding site is available from oligonucleotide ‘E’ of the (Br-dU3)dC2 structure. Supplementary Movie S1 illustrates the cytidine-induced changes at
the third binding site. In Figures 3 and 4, the uridines are coloured magenta, cytidines are yellow, and grey lines show the nucleotides adjoining the
site of interest. Polar hydrogens are included for clarity. Dashed lines indicate hydrogen bonds (<3.5 A˚ between non-hydrogen atoms).
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The C-terminal RRM2 of each polypeptide recognizes
four nucleotides in the 50 region of one oligonucleotide
(dU1–dU4), and the N-terminal RRM1 recognizes four
nucleotides in the 30 region of a separate oligonucleotide
(dU4–dU7) (Figure 2). Consequently, the central dU4 nu-
cleotide is enclosed by RRM1 and RRM2 contributed by
distinct polypeptides (Supplementary Figure S5). Despite
differences in the relative rotation of the two RRMs
among the crystallographically independent complexes,
the central dU4 base continues to engage in similar
U2AF65 contacts among the structures. The K260, N289
and F304 residues that interact with rU4 (here dU4) con-
tribute signiﬁcantly to the U2AF651,2 afﬁnity for poly-rU
RNA (by 36-fold for K260A/N289A double mutation and
73-fold for F304A mutation) (25). Given the importance
of these interactions and the similar interactions, despite
crystallographically independent environments, we
suggest that the rU4/dU4 interactions are the coalescence
of two separable binding sites for nucleotides on U2AF65
RRM1 and RRM2 such that the crystal structure in effect
Figure 4. Structural comparison of U2AF65 RRM1 recognizing uracil versus cytosine. (A) Fifth nucleotide binding sites. The U2AF65 interactions
are nearly identical among the Br-dU5 nucleotides from oligonucleotides ‘E’ and ‘P’ of the Br-dU5 structure and the corresponding dU4 nucleotides
of the Br-dU3 structure. One example of cytidine in the ﬁfth binding site is available from oligonucleotide ‘P’ of the (Br-dU3)dC4 structure.
Supplementary Movie S2 illustrates the cytidine-induced changes at the ﬁfth binding site. (B) Sixth nucleotide binding sites. The U2AF65 interactions
are nearly identical among the dU6 nucleotides from oligonucleotides ‘E’ and ‘P’ of the Br-dU5 structure and the corresponding dU5 nucleotides of
the Br-dU3 structure. The dC6 interactions of the (Br-dU5)dC6 oligonucleotides ‘E’ and ‘P’ differ slightly in the rotation of the R150 side chain and
are shown in separate panels. As shown in C, the movement of R150-A in turn alters dU7-P in the seventh binding site of the (Br-dU5)dC6
oligonucleotide ‘P’. Supplementary Movie S3 illustrates the cytidine-induced changes at the sixth binding site of (Br-dU5)dC6 oligonucleotide ‘P’. (C)
Seventh nucleotide binding sites. Cytidine is bound in the seventh binding sites of both oligonucleotides in the (Br-dU3)dC5 structure. The ﬁnal panel
compares the cytidine-induced shift in the dU7 binding site of the (Br-dU5)dC6 oligonucleotide ‘P’.
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represents eight distinct nucleotide binding sites on the
U2AF65 protein. Accordingly, in-depth analyses of the
U2AF651,2 afﬁnities for uridine tracts of various lengths
suggest a binding site size of 8–9 nucleotides (26). Efforts
to substitute a cytidine at the fourth binding site of the
crystal structures were unsuccessful, possibly owing to the
dual sets of interactions at this site. Instead, we have
determined structures that seek to place cytidines at six
of the U2AF65/nucleotide binding sites.
The U2AF65 RRM2 structure has difﬁculty
accommodating cytidines in the 50 region of the Py tract
The structures of dU2AF651,2 bound to either
(Br-dU5)dC1, (Br-dU5)dC2 or (Br-dU3)dC2 oligonucleo-
tides suggest that the U2AF65 RRM2 has difﬁculty
forming stable interactions with cytidine substitutions in
the 50 half of the bound oligonucleotide (Figure 3). Based
on the 2.2 A˚ resolution Br-dU5 structure, the dU1 of the
oligonucleotide ‘E’ binds a similar site as rU1 of the
original 2.5 A˚ resolution structure of the dU2AF651,2/
rU12 structure (Figure 3A). A bound water molecule
that mediates a hydrogen bond between dU1-E and
T296 of the Br-dU5 structures is likely to be present but
unresolved at the lower, 2.5 A˚ resolution of the
dU2AF651,2/rU12 complex, given that the ‘hydrogen
bond’ between T296 and rU1 of the RNA-bound
complex is relatively long (3.4 A˚). As described in more
depth for the second site, a K328 side chain that engages
the 50 phosphate of the rU1 nucleotide has shifted in the
Br-dU5 structure to interact with the uracil-O4 of the
neighbouring dU2. With the intention of placing a
cytidine at the ﬁrst binding site, we determined the struc-
ture of dU2AF651,2 bound to a Br-dU5 variant with a
single cytidine substituted at the ﬁrst nucleotide
[(Br-dU5)dC1)] at 2.5 A˚ resolution (Figure 3A,
Supplementary Table S1). The four complexes in the crys-
tallographic asymmetric unit of the (Br-dU5)dC1 struc-
ture exhibited the Br-dU in the expected ﬁfth binding
site (Figure 2B, Supplementary Figure S2F). Rather
than attempting to adapt to the differences between
uracil and cytosine (N3-H and O4 compared with N3
and N4-H atoms, respectively), the ﬁrst cytidine (dC1)
became disordered and lacked apparent electron density
in any of the four complexes (Figure 3A). In addition,
electron density for the adjacent dU2 nucleotide could
not be interpreted in one of the dU2AF651,2/
(Br-dU5)dC1 copies (oligonucleotide ‘P’). Although
U2AF65 interactions with the 50 terminal deoxy-ribose nu-
cleotides are weakened by the absence of the 20 hydroxyl
group and terminal phosphate, comparision of the dis-
ordered dC1 and evident dU1 suggests that U2AF65 has
more difﬁculty forming stable contacts with a cytosine
than uracil at the ﬁrst position of the Py tract. One
possible explanation is that the negative charge of the
D293 side chain is less favourable adjacent a
cytosine-N3 than a uracil-N3-H.
To capture a cytidine in the second binding site, we
determined the 2.4 and 2.2 A˚ resolution structures of
dU2AF651,2 bound to the (Br-dU5)dC2 and (Br-dU3)dC2
oligonucleotides, respectively (Figure 3B, Supplementary
Table S1). Both copies of the Br-dU5)dC2 oligonucleotides
in the crystallographic asymmetric unit bound the Br-dU in
the ﬁfth and dC2 in the second binding sites of U2AF65
(Supplementary Figure S2G), whereas only the oligonucleo-
tide ‘P’ of the (Br-dU3)dC2 structure placed the dC2 in the
second binding site. The rU2 of the dU2AF651,2/rU12 struc-
ture chieﬂy interacts by base stacking with glycines G264
and G265 and a single hydrogen bond between the
uracil-O4 and the K329 side chain. The U2AF65 interactions
with the dU2 counterpart of Br-dU5 oligonucleotide
‘E’ remained in a similar location as the rU2, except that
in the absence of prior engagement by the 50 phosphate, the
K328 side chain replaces the hydrogen bond of K329 with
the uracil-O4. The movement of K329 appears to facilitate
formation of a water-mediated hydrogen bond between the
polypeptide backbone and the uracil-O4 in the higher reso-
lution Br-dU5 structure. In the presence of cytosine, the
K328 side chain of the (Br-dU5)dC2 oligonucleotide ‘E’
shifted slightly to avoid the major conformation of the
cytosine exocyclic amine. In the minor alternative conform-
ation of the (BrU5)C2 oligonucleotide ‘E’, the cytosine
moved to accept a hydrogen bond from the backbone
N-H of the glycine residue (G265) (Figure 3B, far right).
The shifts in the dC2 positions in turn disrupt the U2AF65
interactions with the adjacent dU1, which is disordered and
lacks interpretable electron density in any of the structures
with cytidine bound at the second U2AF65 site. The dC2 of
the (Br-dU5)dC2 and (Br-dU3)dC2 ‘P’ oligonucleotides
rotated too stack against the L330 side chains yet otherwise
maintained similar interactions as the major conformation
of oligonucleotides ‘E’ (Supplementary Figure S4C).
Although these structural changes at the 50 terminus of
the oligonucleotide cannot be assumed to parallel the
RNA counterparts, the observed loss of stable U2AF65
interactions suggests that the proximity of a positively
charged K328 or K329 lysine could favour a uracil-O4
over a cytosine-N4H3 at the second position of the Py tract.
As aforementioned, the binding register of one of the
(Br-dU3)dC2 complexes (oligonucleotide ‘P’) places a
cytosine in the second site, where it engages in similar
U2AF65 interactions as the (Br-dU5)dC2 oligonucleotide
‘P’. The binding register for the other (Br-dU3)dC2
complex (oligonucleotide ‘E’) places the cytidine in the
third and the Br-dU in the fourth of the U2AF65
binding sites (Figure 1B, Supplementary Figure S2B), ap-
parently stabilizing one of the two alternative binding
registers of the parental Br-dU3 structure. Among the
structures, only the dU2AF651,2/(Br-dU3)dC2 oligo-
nucleotide ‘E’ bound the Br-dU in the third rather than
fourth or ﬁfth sites, suggesting that the energetic penalty
for ﬁtting a cytidine into the third site is on par with
shifting a Br-dU to a less preferable site.
The cytidine at the third site induces relatively large,
well-ordered changes in the U2AF65 structure
(Figure 3C, Supplementary Movie S1). The U2AF65 inter-
actions are indistinguishable between the rU3 of the
original, RNA-bound structure and the dU3 from either
the ‘E’ or ‘P’ oligonucleotides of the Br-dU5 structure.
Namely, the Q333 side chain and A335 carbonyl respect-
ively engage the uracil-O4 and N3-H in hydrogen bonds.
Three structural changes in the U2AF65 protein are
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observed in response to the uracil-to-cytosine substitution:
(i) the Q333 side chain undergoes a torsional rotation to
accept a hydrogen bond from the cytosine exocyclic
amine; (ii) the backbone carbonyl of R334 moves to
accept a second hydrogen bond from this cytosine
amine; and (iii) the relatively rigid backbone of S336
undergoes a large f torsional rotation from 142 to
+164, which enables the peptide bond with A335 to
donate a hydrogen bond to the cytosine-N3. As the
A335 and S336 residues are located at the C-terminus of
the crystallized construct of U2AF65, the energetic penalty
for adjusting to the third cytidine could be greater and
possibly inﬂuence downstream residues in the context of
the full-length U2AF65 protein.
The U2AF65 RRM1 structure adapts to cytidines in the
30 region of the Py tract
The structures of dU2AF651,2 bound to either
(Br-dU3)dC4, (Br-dU5)dC6 or (Br-dU3)dC5 oligonucleo-
tides suggest that following relatively subtle structural
changes, U2AF65 RRM1 can accommodate cytidine sub-
stitutions in the 30 half of the bound oligonucleotide
(Figure 4). One of the 2.5 A˚ resolution dU2AF651,2/
(Br-dU3)dC4 complexes (oligonucleotide ‘P’) offered a
well-deﬁned view of a cytidine in the ﬁfth binding site
(Figure 4A, Supplementary Figure S2C). In the second
dU2AF651,2/(Br-dU3)dC4 complex of the crystallo-
graphic asymmetric unit (oligonucleotide ‘E’), alternative
binding registers place the cytidine with partial occupancy
in the ﬁfth and sixth binding sites as observed for the
Br-dU3 parent (Figure 1B, Supplementary Figure S2C).
This stabilized binding register for one of the complexes
suggests a slight preference for U2AF65 to accommodate a
cytosine at the ﬁfth over sixth sites. Despite the introduc-
tion of a 5-bromo group, the U2AF65 interactions with the
ﬁfth dU of both ‘P’ and ‘E’ oligonucleotides in the baseline
Br-dU5 structure remain similar to the RNA-bound struc-
ture. Namely, the backbone carbonyl of U2AF65 R228
and the amide of H230 respectively form hydrogen
bonds with the uracil N3-H and O2 groups. Despite
these nucleotide interactions with a relative rigid protein
backbone, U2AF65 readily accommodates the switch to
the N3 hydrogen bond acceptor of the cytosine at the
ﬁfth site. A slight movement of the deoxy-cytidine
relative to the uridine enables the U2AF65 R228
carbonyl to accept an analogous hydrogen bond from
the cytosine exocyclic amine, and the H230-NH –
cytosine-O2 interaction remains unperturbed (Figure 4A,
Supplementary Movie S2). An ordered water molecule
bound to the uracil-O4 also appears to have been lost,
possibly owing to the switch from a hydrogen bond
acceptor to a donor for the cytosine exocyclic amine in
proximity to the U2AF65 K225 and R227 side chains.
U2AF65 undergoes a number of structural changes to
adapt to a cytosine at the sixth binding site (Figure 4B,
Supplementary Movie S3). The Br-dU occupies the ﬁfth
and cytidine the sixth binding sites in both complexes of
the dU2AF651,2/(Br-dU5)dC6 structure (Supplementary
Figure S2H), which is the highest resolution among the
dU2AF651,2 structures (1.9 A˚). The dU6 in both ‘P’ and
‘E’ oligonucleotides of the Br-dU5 structure both exhibit
similar U2AF65 interactions as the RNA counterpart. The
uracil-O4 accepts hydrogen bonds from the backbone
N-H of U2AF65 D231 and H230, the latter of which is
bifurcated by the hydrogen bond donated to the preceding
dU6-O2. The slightly higher resolution of the Br-dU5
compared with the rU12 structure (2.2 A˚ and 2.5 A˚ reso-
lution, respectively) reveals an ordered water molecule
that mediates hydrogen bonds among R150, D231 and
the uracil-N3-H of both ‘P’ and ‘E’ oligonucleotides. In
addition, the R150 side chains of both the ‘P’ and ‘E’
oligonucleotides have rotamers that can donate two
hydrogen bonds to the uracil-O2 of dU6.
Following substitution of the cytosine at the sixth site,
the D231 side chain rotates to accept a direct hydrogen
bond from the cytosine exocyclic amine (Figure 4B). The
introduction of an ordered water molecule enables the
U2AF65 D231 peptide N-H to donate a water-mediated
hydrogen bond to the cytosine exocyclic amine.
Remarkably, RNA binding selects from two alternative
conformations of the R150 side chain that are apparent
in the high resolution structure of the apo-U2AF65 RRM1
(35). The sixth uracil base is only observed to interact with
one of two alternative R150 conformations, whereas the
hydrogen bond pattern of a cytosine is compatible with
either. Accordingly, the sixth cytosine selects a different
alternative conformation in each of the two crystallo-
graphically distinct dU2AF651,2/(Br-dU5)dC6 copies. In
one of the two (Br-dU5)dC6 complexes (oligonucleotide
‘E’), the R150 remains in a similar location as when bound
to uracil, where the side chain contributes two direct
hydrogen bonds to the cytosine-O2 and a water-mediated
hydrogen bond to the cytosine-N3. The R150 side chain
of the other dU2AF651,2/(Br-dU5)dC6 copy (oligonucleo-
tide ‘P’) has rotated to replace the water molecule bound
to the cytosine-N3. This movement of the R150 side chain
alters stacking with the adjacent dU7 base, which in turn
shifts to form a distinct set of apparently favourable inter-
actions with U2AF65, including a direct hydrogen bond
from the uracil N-H to the available oxygen of the D231
side chain and an indirect hydrogen bond via the water
molecule bound to the preceding cytosine amine
(Figure 4C, far right panel). Together, these structural
changes indicate that cytidine is compatible with a
tight network of U2AF65 interactions at the sixth
binding site.
Lastly, the dU2AF65/(Br-dU3)dC5 structure provides
2.2 A˚ resolution views of a cytidine in the seventh
binding site (Supplementary Table S1). The binding regis-
ters of both dU2AF651,2/(Br-dU3)dC5 complexes shifted
to place the Br-dU5 in the fourth and dC5 in the ﬁnal
seventh site (Figure 1B, Supplementary Figure S2D).
The stabilization of this binding register compared with
the mixture of Br-dU3 at the fourth and ﬁfth sites of the
parent suggests a slight preference for cytosine over uracil
at the seventh binding site. By comparison with other
binding sites, the interactions of U2AF65 with nucleotides
in the seventh site are minimal. The seventh uracils of all
the poly-rU-containing structures primarily interact by
aromatic stacking on the R150 side chain of U2AF65. At
the higher resolutions of the Br-dU5 and (Br-dU3)dC5
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structures compared with the rU12 counterpart (2.2 A˚
versus 2.5 A˚ resolutions), a water-mediated hydrogen
bond between the S147 side chain and the uracil-O4 or
cytidine-N4H2 becomes apparent. Following a slight
shift in the position of an intermediary water molecule,
the cytidine at the seventh site of the dU2AF651,2/
(Br-dU3)dC5 structure otherwise continues to stack with
the R150 in a comparable manner as the uracil.
U2AF65 prefers uridines in the 50 region of the Py tract
and tolerates cytidines in the 30 region
The different abilities of the U2AF65 RRM structures
to adapt to cytidines predicted that U2AF65 would
display region-dependent preferences for cytidines and
uridines in the Py tract. To facilitate interpretation of
the crystal structures, we focused on determining the
afﬁnities of the minimal U2AF65 RRM1-RRM2 domain
(U2AF651,2) for core Py tracts derived from the prototyp-
ical adenovirus major late promoter transcript
(rAdML13). Our primary method of steady-state SPR
has the advantage of concurrently monitoring the
apparent binding stoichiometry (Supplementary Figure
S6, see ‘Materials and Methods’ section). ITC experiments
independently corroborated the speciﬁcities determined by
SPR (Supplementary Figure S7).
AdML variants with a few cytidine substitutions in the
Py tract previously were shown to support in vitro splicing
and spliceosome complex formation at levels comparable
with those of the unmodiﬁed pre-mRNA parent, whereas
a polycytidine tract abolishes detectable use of the
adjacent 30 splice site (9). We ﬁrst investigated whether
these splicing activities correlated with the abilities of
U2AF651,2 to bind the Py tract RNAs (Table 1). In agree-
ment with the previously reported splicing activities, the
afﬁnities of U2AF651,2 for Py tracts with one, two and
even three cytidine mutations at the ﬁfth, seventh, ninth or
tenth positions remained similar as for the rAdML13
oligonucleotide. We also found that U2AF651,2 exhibited
little or no detectable binding to a polyC tract of equiva-
lent length [rC(4–11)].
We next compared tracts of three, four or ﬁve uridines
located in either the 50 or 30 regions of a Py tract otherwise
composed of cytidines (Table 1). In all cases, U2AF65
preferred uridines to cytidines in the 50 region of the Py
tract, whereas cytidines could effectively substitute for
uridines in the 30 region. Consistent with the observation
that four nucleotides bind to each U2AF65 RRM and
considering the shared fourth nucleotide at the RRM1/
RRM2 interface, it is not surprising that the U2AF651,2
afﬁnity for a tract of three uridines in the 50 region of the
Py tract decreased slightly relative to four or ﬁve uridines.
The speciﬁcity of U2AF651,2 protein was greatest for the
four-uridine tract (5-fold preference for four consecutive
uridines in the 50 as opposed to 30 regions of an otherwise
cytidine-rich Py tract, respectively named 50-4rU and
30-4rU RNAs, Table 1). Given that the U2AF65 RRM1
and RRM2 respectively binds near the 30 and 50 termini of
Table 1. U2AF65 afﬁnities for degenerate Py tracts
U2AF65 proteina Py tract name Py tract sequenceb <KD> (mM)
c Fold penaltyd
U2AF651,2 rAdML13 C.C.C.U.U.U.U.U.U.U.U.C.C 12.5±1.6 1.0
U2AF651,2 rU13 U.U.U.U.U.U.U.U.U.U.U.U.U 13.1±0.9 1.0
Pyrimidine mutations:
U2AF651,2 rC(5) C.C.C.U.C.U.U.U.U.U.U.C.C 13.9±1.0 1.1
U2AF651,2 rC(7) C.C.C.U.U.U.C.U.U.U.U.C.C 9.3±0.4 0.8
U2AF651,2 rC(9) C.C.C.U.U.U.U.U.C.U.U.C.C 13.7±1.3 1.1
U2AF651,2 rC(10) C.C.C.U.U.U.U.U.U.C.U.C.C 11.9±0.8 0.9
U2AF651,2 rC(7,9) C.C.C.U.U.U.C.U.C.U.U.C.C 11.0±0.6 0.9
U2AF651,2 rC(7,10) C.C.C.U.U.U.C.U.U.C.U.C.C 14.5±0.9 1.2
U2AF651,2 rC(7,9,10) C.C.C.U.U.U.C.U.C.C.U.C.C 11.6±0.8 0.9
U2AF651,2 rC(4,5,8,10) C.C.C.C.C.U.U.C.U.C.U.C.C 27.9±1.3 2.2
U2AF651,2 rU(3)C(4,6,9,10,11) C.C.U.C.U.C.U.U.C.C.C.C.C 14.4±1.1 1.2
U2AF651,2 rC(4–11) C.C.C.C.C.C.C.C.C.C.C.C.C 125±10 10.0
Uridine/Cytidine tracts:
U2AF651,2 50-3rU C.C.U.U.U.C.C.C.C.C.C.C.C 22.0±0.9 1.8
U2AF651,2 30-3rU C.C.C.C.C.C.C.C.U.U.U.C.C 89.5±3.9 7.2
U2AF651,2 50-4rU C.C.U.U.U.U.C.C.C.C.C.C.C 14.3±0.6 (3.5±0.3) 1.1
U2AF651,2 30-4rU C.C.C.C.C.C.C.U.U.U.U.C.C 69.4±3.1 (13.5±0.9) 5.6
U2AF651,2 50-5rU C.C.U.U.U.U.U.C.C.C.C.C.C 14.4±0.8 1.1
U2AF651,2 30-5rU C.C.C.C.C.C.U.U.U.U.U.C.C 45.2±3.4 3.6
U2AF65 mutations:
U2AF651,2MUT 50-4rU C.C.U.U.U.U.C.C.C.C.C.C.C 14.0±1.6 1.1
U2AF651,2MUT 30-4rU C.C.C.C.C.C.C.U.U.U.U.C.C 12.5±1.3 1.0
aThe U2AF651,2 protein comprises the core RRM1 and RRM2 domains connected by the wild-type linker, and the U2AF651,2MUT has four
mutations in RRM2 (D293N/K329Q/L331K/Q333E).
bThe nucleotide substitutions to be compared are emphasized in bold font.
cApparent equilibrium dissociation constants for the indicated U2AF651,2 protein/Py tract combination are averages of at least two experiments, and
a representative sensorgram is shown in Supplementary Figure S6. Afﬁnities determined by ITC are given in parentheses, and representative
isotherms are shown in Supplementary Figure S7. Splicing activities of the rC(10), rC(7,10) and rC(4–11) substrates were reported previously (9).
d‘Fold Penalty’ is the fold decrease in afﬁnity relative to wild-type U2AF651,2 binding the rAdML13 Py tract. >3-fold penalties are highlighted
in bold.
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the Py tract, the region-dependent uridine/cytidine prefer-
ences agreed with the relative ease for the U2AF65 RRM1
structure to accommodate cytidines in comparison with
the RRM2.
Residues in U2AF65 RRM2 contribute to region-dependent
pyrimidine speciﬁcity
We proceeded to test the direct involvement of the
U2AF65 RRM2 in determining the speciﬁcity of U2AF65
for uridines in the 50 region of the Py tract. Based on
the structures, we introduced four mutations within
the RRM2 of U2AF651,2 (U2AF651,2MUT) that were
intended to favour cytidine over uridine binding
(Figure 5A and B): (i) D293N, replacing an aspartate
that would disfavour a cytosine-N3 at the ﬁrst site with
an asparagine side chain, which is expected to form similar
hydrogen bonds with cytosine or uracil; (ii) K329Q,
likewise substituting a ‘neutral’ side chain in place of
a lysine that contributes an unfavourable electrostatic
environment for a cytidine-N4H2 at the second site;
(iii) L331K, changing a leucine to a hydrogen bond
donor that could potential interact with a cytidine-N3 at
the second site; and (iv) Q333E, replacing a glutamine
with a stringent hydrogen bond acceptor for interactions
with a cytidine-N4H2 at the third site. The U2AF
651,2MUT
variant continued to bind the 50-4rU Py tract RNA with
indistinguishable afﬁnity as the wild-type protein,
indicating that the RRM2 mutations did not detectably
penalize recognition of uridines in the 50 region of the Py
tract. As expected based on the crystal structures, the
U2AF651,2MUT afﬁnity for the 30-4rU RNA increased by
5.5-fold to a level comparable with the 50-4rU counterpart,
indicating that the mutated RRM2 had lost the ability to
discriminate against cytidines in the 50 region of the Py
tract (Figure 5C and D). These results directly implicated
RRM2 in determining the preference of U2AF65 for
uridines in the 50 region of the Py tract.
Given the difﬁculties of predicting RRM–RNA inter-
actions (36), we did not attempt to enhance the speciﬁcity
of a promiscuous U2AF65 RRM1. However, several ob-
servations indirectly implicated RRM1 in recognizing the
30 region of the Py tract, including the following: (i) the
U2AF651,2 afﬁnity for these Py tracts is higher than
expected for RRM2 alone, whereas the inter-RRM
linker is not directly involved in RNA binding (26,29),
leaving only RRM1; (ii) the U2AF651,2 afﬁnities for Py
tracts with identical pyrimidine contents depended on
the 50 versus 30 locations of the four uridine tract; and
(iii) the mutations in RRM2 only affect association with
the 30-4rU RNA but have no effect on binding the 50-4rU
RNA. These strong region-dependent effects call for re-
spective contributions by U2AF65 RRM2 in binding the
50 nucleotides and RRM1 in binding the 30 nucleotides of
the 13-mer Py tracts.
Figure 5. U2AF65 RRM2 determines region-dependent uridine/cytidine preferences in Py tracts. (A) Structure of dU2AF651,2 RRM2 bound to
dU1-dU4 (from Br-dU5). The unmodiﬁed counterparts of the mutated residues are shown as ball-and-stick representations and coloured by atom:
carbons, cyan; oxygens, red; nitrogens, blue. (B) Model of U2AF651,2MUT RRM2 showing the predicted interactions of the four mutated D293N/
K329Q/L331K/Q333E residues with cytidines (yellow) (C and D) Bar graphs of the 50-4rU and 30-4rU (shaded) RNAs afﬁnities for the (C) wild-type
U2AF651,2 protein (blue) compared with the (D) D293N/K329Q/L331K/Q333E U2AF651,2MUT protein (yellow).
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Py tract variants select different U2AF65 conformations
The apparent difference in the speciﬁcities for the two
U2AF65 RRMs increased the possibility that U2AF65
adapts to degenerate Py tracts by modulating the
proximities of a promiscuous RRM1 and stringent
RRM2 domains. The prior NMR methods indicated
that a 9-mer poly-rU RNA selects an ‘open’ U2AF651,2
conformation with a side-by-side arrangement of the
RRMs. In the absence of RNA, the ‘open’ U2AF651,2
conformation was suggested to be minor relative to a
major ‘closed’ conformation, in which the RNA binding
surface of RRM1 is masked by RRM2 (26). Although
broader than the distribution detected by NMR
methods, we also observe a range of solution conform-
ations for the apo-U2AF651,2 protein by SAXS (37).
Here, we further investigated the inﬂuence of binding Py
tracts that have distinct cytidine compositions on the dis-
tribution of U2AF65 conformations (Figure 6). To ensure
that the scattering data primarily reﬂect the protein rather
than the RNA conformations, we used a larger U2AF65
construct (U2AF651,2U) that included the C-terminal
UHM in addition to the RRM1 and RRM2
(Figure 6A). The U2AF65 UHM lacks detectable RNA
afﬁnity in isolation (39), and NMR spectra suggest that
the U2AF651,2 contacts the Py tract in a similar manner in
the presence of the UHM domain (26). We also have
shown that additional residues surrounding the core
U2AF651,2 fragment have little detectable inﬂuence on
the conformational ensemble (37). As such, we use the
U2AF651,2U protein as a means to study the inﬂuence of
different Py tract RNA sequences on the U2AF65 inter-
domain proximities in the solution pool. We compared the
effects of three representative Py tracts on the distribution
of U2AF651,2U conformations. These Py tracts include a
homogeneous 13-mer uridine tract (rU13), the unmodiﬁed
AdML Py tract composed of an eight-uridine core
embedded within ﬁve cytidines (rAdML13) and the
rC(7,9,10) variant with three internal cytidine substitu-
tions. All three RNAs share a 13-nucleotide length and
Figure 6. Py tract sequences redistribute the U2AF65 conformational ensemble. (A) Schematic representation of the U2AF6512U domain and Py tract
RNA sequences used for SAXS experiments. (B) Experimental SAXS proﬁles (coloured circles) compared with proﬁles calculated from the best
ﬁtting ensembles (black lines). Intensity data are offset for clarity. Colours are consistent throughout: rU13, magenta; rAdML13, green; rC(7,9,10),
orange. The SAXS proﬁle of apo-U2AF6512U (‘apo’, blue) from reference (38) is shown for comparison. (C) The DMAX distributions of ensembles
calculated using EOM (33) (solid coloured lines) for U2AF6512U alone or bound to the rU13 RNA compared with the randomized starting pool
(dashed grey line). Lower case letters mark the DMAX values of the models shown in E. (D) The DMAX distributions of U2AF
6512U ensembles bound
to rU13, rAdML13 or rC(7,9,10) Py tract RNAs. (E) Representative models from the EOM analyses and corresponding DMAX values.
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comparable afﬁnities for U2AF65, despite the different
number of cytidines (Figure 6A).
The SAXS data sets for U2AF651,2U with and without
RNA appear monodisperse and extend beyond
q=0.30 A˚1 (Figure 6B, Supplementary Figure S8). In
the absence of RNA, the average solution shape of the
apo-U2AF651,2U protein comprises three lobes corres-
ponding to the relatively separated RRM1, RRM2 and
UHM domains (38). We re-analysed the
apo-U2AF651,2U SAXS data using an ensemble
approach (33), in which a subset of 20 structures that
best ﬁt the data was selected from a starting pool of
10 000 conformations comprising the RRM1, RRM2
and UHM structures tethered in randomized orientations
and proximities by ab initio linkers. As observed for the
apo-U2AF651,2 (37), the distribution of selected
apo-U2AF651,2U conformations closely matches that of
the randomized starting pool (Figure 6C). Although no
change in the average molecular dimensions was
apparent following addition of the Py tract RNAs (38)
(Supplementary Table S2), the ensemble analyses
revealed distinct changes in the distribution of the
solution conformations (Figure 6C–E). The distribution
of the U2AF651,2U conformations following association
with the homogeneous rU13 tract remained broad, but
the molecular dimensions of the most prevalent conform-
ations were slightly larger than for the apo-protein
(120 A˚ compared with 100 A˚). The conformational
ensemble of the rAdML13-bound U2AF
651,2U also
remained broad, but the most prevalent selected conform-
ations shifted to back to a compact arrangement of the
U2AF65 RRMs (100 A˚). The cytidine-interrupted
rC(7,9,10) tract increased the prevalence of more
extended U2AF651,2U conformations (150–180 A˚) but
lacked clear preference for a conformation of any given
size. In summary, the rAdML13, rU13 and rC(7,9,10) Py
tracts select subsets of U2AF65 conformations with
distinct inter-RRM proximities from the pre-existing
solution ensemble of the apo-protein.
DISCUSSION
Here, a series of high resolution U2AF65 structures
suggest that a subset of binding sites in the N-terminal
RRM1 can tolerate cytidine substitutions of uridine-rich
Py tracts more readily than others in the C-terminal
RRM2 (Figures 3 and 4). We note that the two
deoxy-cytidines in the 50 terminal positions of the
RRM2-bound oligonucleotide are poorly ordered and
could be inﬂuenced by the minimal backbone. However,
the increased disorder of the cytosines relative to the
uracils of the dU counterparts is likely to reﬂect
weakened interactions that can be extended to U2AF65
recognition of Py tract RNAs. Accordingly, line broaden-
ing of the NMR signals for U2AF65 bound to poly(rU)
suggest some ﬂexibility in the RNA interface (26). In light
of the C-to-N-terminal orientation of the U2AF65 RRMs
bound to the 50–30 orientation of the bound RNA strand,
the discrimination of U2AF65 against cytidines in the 50
region of Py tracts and permissiveness towards cytidines in
the 30 region supports the structural conclusion that
RRM2 has more difﬁculty adapting to cytidines than
does RRM1 (Table 1). Site-directed mutagenesis
conﬁrms a role for the U2AF65 RRM2 in specifying
uridines near the 50 region of the Py tract and indirectly
implicates RRM1 in adapting to the 30 region (Figure 5).
Complementary SAXS studies further demonstrate that
Py tracts with different cytidine contents select U2AF65
conformations with different inter-RRM spacings from
the solution ensemble (Figures 6 and 7).
The prevalent conformations detected by SAXS of the
apo-U2AF651,2U protein are likely to correspond to the
‘closed’ NMR model, with the distinction that the SAXS
analyses provides evidence that elongated conformations
beyond the radius of the paramagnetic relaxation
enhancement labels contribute to the solution ensemble
(37). Given that the molecular dimensions of the ‘open’
and ‘closed’ U2AF65 models are comparable at the reso-
lution of the SAXS analyses, the most prevalent conform-
ations of the U2AF651,2U/AdML13 complex are likely to
correspond to ‘open’, side-by-side conformations binding
the central eight uridines of the AdML13 RNA compar-
able with the NMR model of the U2AF651,2/rU9 complex
(26). We suggest that the increased molecular dimensions
of the dominant U2AF651,2U/rU13 conformations arises
from the availability of distal RRM binding sites along
the longer uridine tract. The U2AF651,2U/rC(7,9,10)
ensemble lacks a dominant conformation, which is con-
sistent with a model in which the U2AF65 RRM2 speciﬁes
the remaining three contiguous uridines, whereas RRM1
is compatible with a number of cytidine-containing
binding sites near the 30 end of the Py tract sequence
(e.g. two redundant CUCC motifs at nucleotides 7–10 or
10–13).
Together, the U2AF65 structures and binding prefer-
ences reported here support and reﬁne a recent model
for U2AF65 multi-domain conformational selection of
pre-mRNA splice sites, which is based on elegant NMR
data and biochemical experiments (26). A main feature of
this model is that a minor ‘open’ conformation of
apo-U2AF65 is selected by Py tract binding, whereas a
major, ‘closed’ conformation, in which the RRM1 RNA
binding surface is occluded by interactions with the
a-helical ‘back’ of RRM2 and hence unavailable for
RNA binding. Based on the structural and afﬁnity data
that we present here and in reference (37), we propose
three key revisions of this model to better explain the
ability of U2AF65 to recognize degenerate pre-mRNA
splice sites. First, we note that the RRM masked by the
‘closed’ conformation of apo-U2AF651,2 is promiscuous
for RNA sequences. This observation suggests that the
‘closed’ conformation could protect U2AF65 against
non-speciﬁc RNA interactions and hence inappropriate
splice site activation. Second, as shown here for the case
of R150 at the seventh nucleotide binding site, local con-
formational selection of pre-existing alternative side chain
conformers can contribute to the ability of U2AF65 to
adapt to cytidine substitutions. Third, we suggest that
the two-state model could be an oversimpliﬁcation of
the U2AF65 conformations available for selection by de-
generate Py tracts. Conformations similar to the ‘open’
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and ‘closed’ NMR-based U2AF65 conformations contrib-
ute to the solution ensembles detected by X-ray scattering.
However, both of these NMR structures are characterized
by close contacts between the two U2AF65 RRMs, which
are insufﬁcient to describe the X-ray scattering data of the
apo-U2AF651,2 protein (37). Instead, the apo-U2AF651,2
and U2AF651,2U scattering data are better ﬁt by broad
conformational ensembles closely resembling the
randomized starting pools of RRM (and UHM)
domains connected by ab initio linkers. This subtle dis-
crepancy over the relative populations of compact
‘closed’/‘open’ and more extended conformations
suggests that didactic studies are needed to better under-
stand the outcomes of PRE and SAXS techniques when
applied to multi-domain proteins. Regardless, distinct
U2AF65 conformations with increased molecular dimen-
sions are enriched in the ensembles bound to the homoge-
neous rU13 or three-uridine rC(7,9,10) Py tracts. This
ﬁnding emphasizes that the U2AF65 RRM1 and RRM2
can participate independently in identifying 30 splice site
sequences, which increases the diversity of Py tracts that
can be recognized by U2AF65.
In summary, we propose that degenerate Py tracts se-
lect distinct proximities of a promiscuous RRM1 and
stringent RRM2 from the apo-U2AF65 conformational
ensemble, which would shift interspersed cytidines to
permissive U2AF65 sites without penalizing RNA
afﬁnity (Figure 7). Although this result emphasizes con-
formational selection over an induced ﬁt mechanism of
U2AF65/RNA recognition, the apparently weak
association between the RRMs could facilitate
‘ﬁne-tuning’ of initial U2AF65 interactions with the
RNA. This revised model for U2AF65 recognition of
diverse metazoan splice sites clariﬁes prior site-speciﬁc
cross-linking analyses that demonstrated broad,
overlapping binding sites for U2AF65 RRM1 and
RRM2 along the Py tracts of pre-mRNAs (40). In light
of the crystal and SAXS structures, the range of cross-
linking patterns arises from the independent adjustment
of the U2AF65 RRM1 or RRM2 binding registers along
a degenerate Py tract. We note that U2AF65 can accom-
modate up to ﬁve consecutive cytidines in a Py tract
without altering RNA afﬁnity or pre-mRNA splicing
(Table 1) (6,7,9). By contrast, continuous stretches of cyti-
dines saturate the cytidine-compatible binding sites of
U2AF65. As such, these cytidines are forced to engage
the stringent U2AF65 sites, which strongly inhibits
U2AF65-dependent RNA binding and pre-mRNA
splicing.
Our results highlight the ability of a promiscuous
RRM1 and speciﬁc RRM2 to independently seek compat-
ible binding sites as key factors for human U2AF65 to
recognize degenerate splice site signals. As these studies
are focused on the human U2AF65 homologue, it
remains possible that a ‘closed’ U2AF65 conformation
plays a greater role in organisms with short, uridine-rich,
consensus Py tracts at the 30 splice sites, such as
Caenorhabditis elegans (41) or Saccharomyces cerevisiae
(42). In humans, this model for U2AF65 – pre-mRNA
splice site recognition is likely to have important
Figure 7. Model for conformational selection of U2AF65 RRM1-RRM2 by diverse Py tracts. Selection of apo-U2AF651,2 conformations by binding
the rU13, rAdML13 and rC(7,9,10) Py tracts used in this study. Representative conformations of tandem RRMs from the selected ensembles are
shown with space-ﬁlling graphics. Although linear RNA sequences are shown for clarity, the 30 splice site is likely to exhibit curvature in
three-dimensions (38).
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implications for disease-associated mutations. For
example, shortening in the length of the Py tract preceding
a splice acceptor site of the cystic ﬁbrosis transmembrane
conductance regulator (cftr) gene is the most common
defect in men with cystic ﬁbrosis and infertility owing to
congenital bilateral absence of the vas deferens (13).
Normal phenotypes are produced by Py tracts that have
stretches of 9 Us (UUUUUUUUUAACAG) and 7 Us (U
GUUUUUUUAACAG), whereas splicing of the
associated 30 splice site is nearly abolished by shortening
of the Py tract to 5 Us (UGUGUUUUUAACAG) (12).
Based on the results presented here, the TG expansion in
the 5’ region of the cftr Py tract is likely to interfere with
the sequence-speciﬁc association of the U2AF65 RRM2.
Future studies will illuminate further roles for conform-
ational selection in spliceosome assembly at regulated
pre-mRNA splice sites and its consequences for human
genetic disease.
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